The pancreatic stellate cell: a star on the rise in pancreatic diseases
Food and Drug Administration (FDA), BPC-157 is not approved for any human therapeutic indication and has been restricted from use in compounding pharmacies due to a lack of safety data
Recent research has illuminated the gut-liver axis in MASLD pathogenesis ( Animal model metabolomics studies reveal that HFD-induced NAFLD is characterized by hepatic saturated fatty acid (myristic acid, palmitic acid) and monounsaturated fatty acid (oleic acid) accumulation, accompanied by decreased gluconeogenic amino acid (glycine, alanine, aspartic acid, glutamic acid, proline) levels ( Optimal L-carnitine dosing requires further clarification
Secher A, Jelsing J, Baquero AF, Hecksher-Srensen J, Cowley MA, Dalbge LS, et al